Therapeutic Area

Psychiatry

Therapeutic area intelligence for Psychiatry with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 8
Catalysts: 0
Companies: 2

Companies

Pfizer →

Torrent Pharmaceuticals →

Assets

Recent signals(8)

ClinicalJune 21, 2026

Study on Predictors of PTSD Relapse in Children and Families

This study aims to identify clinical and neuropsychological markers that may predict PTSD relapse in children and their families.

StrategyJune 21, 2026

FDA Grants AP Status for Risperidone ANDA077494 Submission

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Risperidone under application number ANDA077494.

ClinicalJune 19, 2026

NIMH Study on Brain Function in Pediatric Bipolar Disorder

The NIMH is conducting a study to investigate severe mood dysregulation in children aged 7-17, focusing on symptoms and brain changes.

ClinicalJune 18, 2026

ACT vs CBT Trial for Psychological Distress in HIV/AIDS Patients

A randomized controlled trial is underway comparing Acceptance and Commitment Therapy and Cognitive Behavioral Therapy in HIV/AIDS patients.

ClinicalJune 16, 2026

Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients

A Phase III trial demonstrated that Ashwagen® significantly reduced anxiety and stress markers in patients with hypertension.

ClinicalJune 11, 2026

Dapagliflozin vs Metformin for Antipsychotic-Induced Weight Gain in Clinical Trial

A clinical trial is underway to compare the effectiveness of dapagliflozin and metformin in managing weight gain from antipsychotic medications.

ClinicalJune 10, 2026

Study Compares PE Therapy, Pharmacotherapy, and Combination for PTSD in Veterans

A randomized trial will compare the effectiveness of Prolonged Exposure therapy, paroxetine, venlafaxine, and their combination in veterans with PTSD.

CompetitiveJune 10, 2026

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

Torrent's ANDA for Lurasidone Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Pediatric Bipolar Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.